Webinar: Red Blood Cell Partitioning Studies to Improve Accuracy in Pharmacokinetics (PK) Calculations
Presenter: Steven McGreal, Ph.D., Research Scientist in Contract Services & Pallavi Limaye, Ph.D., Director of Scientific Consulting
Pharmacokinetic (PK) parameters of a new drug candidate are typically determined by measuring the drug’s concentration in plasma. However, many drugs have the potential to bind to or diffuse into red blood cells (RBCs), and because RBCs comprise at least 99% of cellular space in blood, this binding potential could significantly impact drug clearance and cause inaccuracies in PK calculations. Red Blood Cell Partitioning assays are designed to determine the blood to plasma ratio of your drug at three concentrations, provide red blood cell distribution percentage, and measure stability… Read more.
In this webinar, SEKISUI XenoTech study director Dr. Steven McGreal will cover study design elements and other considerations like timing and characteristics of drugs with high RBC partitioning. He will discuss impacts on PK calculations and provide examples of how RBC partitioning rates can cause errors downstream if not properly investigated early in drug development. He will be joined by Dr. Pallavi Limaye, Director of Scientific Consulting, for a Q&A session following the presentation.
Register to Receive a Link to the Recording & Slides:
About the Presenter:
Dr. Steven McGreal received his Ph.D. in Toxicology from the University of Kansas Medical Center in 2017 and later that year joined SEKISUI XenoTech. Dr. McGreal is a Research Scientist in the Contract Services division, serving as Study Director for nonclinical studies including drug metabolism, enzyme induction, and enzyme inhibition. He is also responsible for review and interpretation of data, communicating results to sponsors, and responding to Quality Assurance audits. Dr. McGreal is a published author on six peer-reviewed studies and is trained to meet compliance standards of Good Laboratory Practices (GLP) Organisation for Economic Co-operation and Development (OECD) Principles of GLP, and/or Japan Ministry of Health and Welfare (MOHW) Good Laboratory Practice Standards (Ordinance No. 21, March 26, 1997).
Dr. Pallavi Limaye is a Director in the Scientific Consulting department. Pallavi completed her Ph.D. in Toxicology from The University of Louisiana and her postdoctoral research in the Department of Pathology at University of Pittsburgh Michalopoulos and subsequently at the Department of Pharmacology, Toxicology, and Therapeutics at University of Kansas Medical Center. Dr. Limaye originally joined SEKISUI XenoTech in 2011 as a Research Scientist and served as a study director for in vitro drug metabolism studies. In 2013, she joined Xenometrics LLC, as a Senior Scientist and served as a study director for regulated nonclinical IND- and NDA-enabling toxicology studies. From 2018 to 2020 Dr. Limaye worked at MRIGlobal as a Principal Scientist and oversaw nonclinical toxicology and animal health studies, as well as contributed to containment research with select chemical agents. Recently Dr. Limaye joined SEKISUI XenoTech’s consulting team and provides input on drug-drug interaction study needs for sponsors. Dr. Limaye has published several original research articles in various journals (Hepatology, Toxicological Sciences among others) and has also contributed many book chapters in the field of toxicology and liver pathobiology. Dr. Limaye is also actively involved in scientific societies and currently serves on the Program Committee of The American College of Toxicology and is the current President-elect of the Central States regional chapter of The Society of Toxicology.